Medicover MCOV B
This picture changes. Follow Medicover free — email when the signal or risk changes + a Sunday weekly brief.
Follow Medicover freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 23 Jul 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Hold after the post-earnings move; consider adding gradually if margin expansion persists in coming quarters and net debt/EBITDA continues trending down toward targets.
The Q2 result confirmed stable organic growth and slight deleveraging but left execution and jurisdiction risks unchanged, supporting a continued hold stance.
Market sentiment
9/10
↑
Trend: Improving
Sentiment improves further on the price move and a potential strategic India transaction (possible value crystallisation), but near-term uncertainty increases around outcome, valuation and timing of any deal.
Price context
The share trades around 226.5 SEK after a modest post-report gain and sits in the middle of its 52-week range, indicating the market awaits clearer evidence of sustained margin improvement.
Risk assessment
7/10
Dilution:
Low
Profitable; primarily funded via cash flow/debt
Jurisdiction:
Medium
CEE and India exposure; FX and geopolitical factors
Execution:
Medium
High M&A and build-out pace requires strong integration
Recent changes
- The report confirmed stable growth and margins, driving the subsequent share price increase.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Medicover is an international provider of private healthcare and diagnostic services, with a strong footprint in Central & Eastern Europe and India. The company is growing both organically and through acquisitions, with an emphasis on margin improvement and integration. Leverage is relatively high, but the business is profitable and cash-flow generative.
Sector:
Private healthcare and diagnostics
Type:
Other
Next report
4 Nov 2026
Q3
Catalysts
Unknown
Potential sale of Indian hospital operations
High
Horizon:
Bull case
Stable organic growth and continued margin expansion in Diagnostic Services can support the share going forward.
Bear case
Elevated leverage and geopolitical uncertainty in CEE and India may cap upside.
Signal rationale (informational)
The Q2 result confirmed stable organic growth and slight deleveraging but left execution and jurisdiction risks unchanged, supporting a continued hold stance.
Recent news
- The Q2 report was published on 22 July with revenue of 640.4 MEUR and adjusted EBITDA of 109.2 MEUR, in line with expectations. The share rose 2.3 % during the week after the release.
Key figures
Revenue
Q2 2026
EUR 640M
EBITDA
Q2 2026
EUR 107M
Net income
Q2 2026
EUR 23.9M
Price & valuation
Last close
SEK 231
1 week
+3.4 %
3 months
+15.3 %
12 months
-14.4 %
From 52w high
-15.0 %
From 52w low
+27.8 %
Exchange
Stockholm
Sector
Private healthcare and diagnostics
This picture changes. Follow Medicover free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.